Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;54(6):2245-53.
doi: 10.1002/hep.24651.

Human immunodeficiency virus and liver disease forum 2010: conference proceedings

Kenneth E Sherman  1 , David L Thomas, Raymond T Chung
Affiliations

Human immunodeficiency virus and liver disease forum 2010: conference proceedings

Kenneth E Sherman et al. Hepatology. 2011 Dec.

Abstract

Liver disease continues to represent a critical mediator of morbidity and mortality in those with human immunodeficiency virus (HIV) infection. The frequent presence and overlap of concomitant injurious processes, including hepatitis C virus and hepatitis B virus infections, hepatoxicity associated with antiretroviral therapeutic agents, alcohol, and other toxins, in the setting of immunosuppression lead to rapid fibrotic progression and early development of end-stage liver disease. This conference summary describes the proceedings of a state-of-the-art gathering of international experts designed to highlight the status of current research in epidemiology, natural history, pathogenesis, and treatment of HIV and liver disease.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: Unrestricted educational grants from pharmaceutical sponsors to support this meeting were provided by Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Three Rivers Pharmaceuticals, LLC, and Vertex Pharmaceuticals, Inc. Continuing Medical Education credit and content oversight were provided by Medical Education Resources, Inc. Dr. Sherman advises and received grants from Merck, Vertex, SciClone, and Roche. He advises Bristol-Myers Squibb, GlaxoSmithKline, Baxter, and Regulus. He received grants from Gilead, Boehringer Ingelheim, Siemens, and Anadys. He holds other interests with Pfizer, Tibotec, and Medpace.

Figures

Fig. 1
Fig. 1
2010 current treatment guidelines for preferred initial antiretroviral regimens for HIV/HCV-coinfected patients. Rating of recommendation: A = strong; B = moderate; C = optional. Rating of evidence: I = data from randomized, controlled trials; II = data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = expert opinion (www.aidsinfo.nih.-gov/guidelines; accessed on June 14, 2011).
Fig. 2
Fig. 2
(A) Improvement in SVR in Caucasian naïve patients with TVR is greater with the IL-28b T allele. P, PEG-IFN; R, RBV; #, weeks of treatment; T, TVR. Figure created from data presented by Jacobson et al., EASL 2011. (B) Improvement in SVR in naïve patients with BOC is greater with the IL-28b T allele. P, PEG-IFN; R, RBV; #, weeks of treatment; RGT, response-guided therapy. Figure created from data presented by Poordad et al., at the 46th Annual Meeting of the International Liver Congress by the European Association for the Study of the Liver, March 30-April 3, 2011, Berlin, Germany.
Fig. 3
Fig. 3
Higher week 12 response rates in HCV/HIV-coinfected patients in all groups taking TPV/Peg/R. Peg, PEG-IFN; R, RBV. Figure created from data presented by Sulkowski et al. at the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.
See this image and copyright information in PMC

References

    1. Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: the French national Mortalite 2005 study. J Hepatol. 2009;50:736–745. - PubMed
    1. Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056–1063. - PubMed
    1. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21:2209–2216. - PubMed
    1. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, et al. Slower fibrosis progression in HIV/ HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47–55. - PubMed
    1. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis. 2009;49:1274–1282. - PubMed

Publication types

MeSH terms